OptiMag Neuro Mixed Berry 60 Serv by Xymogen

OptiMag Neuro Mixed Berry 60 Serv

Xymogen

$74.99
(No reviews yet) Write a Review
SKU:
XY-OPMAGN-1
Availability:
Usually Ships in 48 to 72 Hours
Already Registered?
How to Gain Access to Store?

OptiMag Neuro Mixed Berry 60 Serv by Xymogen

OptiMag Neuro Mixed Berry 60 serv is a brain health supplement formulated by Xymogen.* It may support a plethora of functions, including cognitive health, synapse function, stress management, sleep quality, and healthy mood.* The product is based on two types of magnesium to improve the levels of this nutrient in your brain.*

Who Should Consider OptiMag Neuro Mixed Berry 60 Servings?

Consider taking OptiMag Neuro Mixed Berry 60 servings if you:

  • want to improve your brain health*
  • wish to support your cognitive function*
  • do not deliver sufficient magnesium in your diet*

The Potential Effects of OptiMag Neuro Mixed Berry 60 Servings by Xymogen

OptiMag Neuro Mixed Berry 60 serv may:

  • support healthy brain magnesium levels*
  • promote healthy synapse number and function*
  • strengthen your cognitive health*
  • support stress management, sleep quality and mood*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. For more information about OptiMag Neuro Mixed Berry 60 Serv, book a FREE product consultation.

Recommendation:
Xymogen suggests dissolving one level scoop of OptiMag Neuro Mixed Berry in 4 oz water and consume once or twice daily, or use as directed by your healthcare professional.

Serving Size: 1 Scoop (about 2.4 g)
Servings Per Container: About 60

Amount Per Serving:
Calories 5
Total Carbohydrate 2 g
Magnesium 200 mg
(as di-magnesium malateS1, magnesium L-threonateS2, and magnesium lysinate
glycinate chelateS1))
Magnesium L-threonateS2 1 g

Other Ingredients: Citric acid, malic acid, natural flavors (no MSG), stevia leaf extract, and anthocyanin extract (color).

Does Not Contain: Wheat, gluten, yeast, soy protein, animal and dairy products, fish, shellfish, peanuts, tree nuts, egg, sesame, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, and artificial preservatives.

Storage:
Keep closed in a cool, dry place out of reach of children.

Caution:
Consult your healthcare professional prior to use. Individuals taking medication should discuss potential interactions with their healthcare professional. Do not use if tamper seal is damaged.

Trademarks:
S1. Albion® and TRAACS® are registered trademarks of Albion Laboratories, Inc.
S2. Magtein® is protected under a family of U.S. Patents and Pending Patents and is protected worldwide. Magtein® is a registered trademark of Magceutics®, Inc. and is distributed exclusively by AIDP, Inc.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

 Click here to view Data Sheet

LEGAL NOTICE: Xymogen's Exclusive Professional Formulas are available through select licensed health care professionals. The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited. covenanthealthproducts.com makes XYMOGEN formulas available only to patients of our clinic. If you are a patient of covenanthealthproducts.com, you may inquire about XYMOGEN by calling (800) 627-6518

References:

  1. Abumaria, N., Luo, L., Ahn, M., et al. (2013). Magnesium supplement enhances spatial-context pattern separation and prevents fear overgeneralization. Behavioral Pharmacology, 24(4), 255–263. [PMID: 23764903]
  2. Abumaria, N., Yin, B., Zhang, L., et al. (2011). Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. Journal of Neuroscience, 31(42), 14871–14881. [PMID: 22016520]
  3. Abbasi, B., Kimiagar, M., Sadeghniiat, K., et al. (2012). The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial. Journal of Research in Medical Sciences, 17(12), 1161–1169. [PMID: 23853635]
  4. Eby, G. A., & Eby, K. L. (2006). Rapid recovery from major depression using magnesium treatment. Medical Hypotheses, 67(2), 362–370. [PMID: 16542786]
  5. Fromm, L., Heath, D. L., Vink, R., et al. (2004). Magnesium attenuates post-traumatic depression/anxiety following diffuse traumatic brain injury in rats. Journal of the American College of Nutrition, 23(5), 529S–533S. [PMID: 15466958]
  6. Held, K., Antonijevic, I. A., Künzel, H., et al. (2002). Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans. Pharmacopsychiatry, 35(4), 135–143. [PMID: 12163983]
  7. Hornyak, M., Voderholzer, U., Hohagen, F., et al. (1998). Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: An open pilot study. Sleep, 21(5), 501–505. [PMID: 9703590]
  8. Li, W., Yu, J., Liu, Y., et al. (2014). Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. Molecular Brain, 7(1), 65. [PMID: 25213836]
  9. Liu, G., Weinger, J. G., Lu, Z. L., et al. (2015). Efficacy and safety of mmfs-01, a synapse density enhancer, for treating cognitive impairment in older adults: A randomized, double-blind, placebo-controlled trial. Journal of Alzheimer’s Disease, 49(4), 971–990. [PMID: 26519439]
  10. Mickley, G. A., Hoxha, N., Luchsinger, J. L., et al. (2013). Chronic dietary magnesium-L-threonate speeds extinction and reduces spontaneous recovery of a conditioned taste aversion. Pharmacology Biochemistry and Behavior, 106, 16–26. [PMID: 23474371]
  11. Moshfegh, A. J., Goldman, J. D., Ahuja, J. K., et al. (2009). U.S. Department of Agriculture, Agricultural Research Service. What we eat in America, NHANES 2005-2006. Usual nutrient intakes from food and water compared to 1997 dietary reference intakes for vitamin D, calcium, phosphorus, and magnesium. Retrieved November 21, 2014, from http://www.ars.usda.gov/SP2UserFiles/Place/80400530/pdf/0506/usual_nutrient_intake_vitD_ca_phos_mg_2005-06.pdf
  12. Pochwat, B., Szewczyk, B., Sowa-Kucma, M., et al. (2014). Antidepressant-like activity of magnesium in the chronic mild stress model in rats: Alterations in the NMDA receptor subunits. International Journal of Neuropsychopharmacology, 17(3), 393–405. [PMID: 24067405]
  13. Slutsky, I., Abumaria, N., Wu, L. J., et al. (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron, 65(2), 165–177. [PMID: 20152124]
  14. Slutsky, I., Sadeghpour, S., Li, B., et al. (2004). Enhancement of synaptic plasticity through chronically reduced Ca2+ flux during uncorrelated activity. Neuron, 44(5), 835–849. [PMID: 15572114]
  15. Wang, D., Jacobs, S. A., & Tsien, J. Z. (2014). Targeting the NMDA receptor subunit NR2B for treating or preventing age-related memory decline. Expert Opinion on Therapeutic Targets, 18(10), 1121–1130. [PMID: 25152202]